352 related articles for article (PubMed ID: 18026200)
1. Burden of illness of neovascular age-related macular degeneration in Canada.
Cruess A; Zlateva G; Xu X; Rochon S
Can J Ophthalmol; 2007 Dec; 42(6):836-43. PubMed ID: 18026200
[TBL] [Abstract][Full Text] [Related]
2. Burden and health care resource utilization in neovascular age-related macular degeneration: findings of a multicountry study.
Soubrane G; Cruess A; Lotery A; Pauleikhoff D; Monès J; Xu X; Zlateva G; Buggage R; Conlon J; Goss TF
Arch Ophthalmol; 2007 Sep; 125(9):1249-54. PubMed ID: 17846366
[TBL] [Abstract][Full Text] [Related]
3. [Neovascular age-related macular degeneration in Germany. Encroachment on the quality of life and the financial implications].
Pauleikhoff D; Scheider A; Wiedmann P; Gelisken F; Scholl HP; Roider I; Mohr A; Zlateva G; Xu X
Ophthalmologe; 2009 Mar; 106(3):242-51. PubMed ID: 18709375
[TBL] [Abstract][Full Text] [Related]
4. Economic burden of bilateral neovascular age-related macular degeneration: multi-country observational study.
Cruess AF; Zlateva G; Xu X; Soubrane G; Pauleikhoff D; Lotery A; Mones J; Buggage R; Schaefer C; Knight T; Goss TF
Pharmacoeconomics; 2008; 26(1):57-73. PubMed ID: 18088159
[TBL] [Abstract][Full Text] [Related]
5. Burden of illness, visual impairment and health resource utilisation of patients with neovascular age-related macular degeneration: results from the UK cohort of a five-country cross-sectional study.
Lotery A; Xu X; Zlatava G; Loftus J
Br J Ophthalmol; 2007 Oct; 91(10):1303-7. PubMed ID: 17504847
[TBL] [Abstract][Full Text] [Related]
6. Burden of illness of bilateral neovascular age-related macular degeneration in Spain.
Ruiz-Moreno JM; Coco RM; García-Arumí J; Xu X; Zlateva G
Curr Med Res Opin; 2008 Jul; 24(7):2103-11. PubMed ID: 18547463
[TBL] [Abstract][Full Text] [Related]
7. [Humanistic burden and health resource utilization among neovascular age-related macular degeneration patients in France].
Soubrane G; Zlateva G; Xu X; Buggage R; Kosa M
J Fr Ophtalmol; 2008 Feb; 31(2):138-45. PubMed ID: 18401314
[TBL] [Abstract][Full Text] [Related]
8. Eye-related medicare costs for patients with age-related macular degeneration from 1995 to 1999.
Coleman AL; Yu F
Ophthalmology; 2008 Jan; 115(1):18-25. PubMed ID: 17572499
[TBL] [Abstract][Full Text] [Related]
9. Health- and vision-related quality of life among patients with choroidal neovascularization secondary to age-related macular degeneration at enrollment in randomized trials of submacular surgery: SST report no. 4.
Dong LM; Childs AL; Mangione CM; Bass EB; Bressler NM; Hawkins BS; Marsh MJ; Miskala P; Jaffee HA; McCaffrey LA;
Am J Ophthalmol; 2004 Jul; 138(1):91-108. PubMed ID: 15234287
[TBL] [Abstract][Full Text] [Related]
10. Responsiveness of the National Eye Institute Visual Function Questionnaire to progression to advanced age-related macular degeneration, vision loss, and lens opacity: AREDS Report no. 14.
Lindblad AS; Clemons TE
Arch Ophthalmol; 2005 Sep; 123(9):1207-14. PubMed ID: 16157800
[TBL] [Abstract][Full Text] [Related]
11. Responsiveness of the National Eye Institute Visual Function Questionnaire to changes in visual acuity: findings in patients with subfoveal choroidal neovascularization--SST Report No. 1.
Miskala PH; Hawkins BS; Mangione CM; Bass EB; Bressler NM; Dong LM; Marsh MJ; McCaffrey LD;
Arch Ophthalmol; 2003 Apr; 121(4):531-9. PubMed ID: 12695250
[TBL] [Abstract][Full Text] [Related]
12. Investigating the burden of wet macular degeneration.
Mitchell J
Arch Ophthalmol; 2007 Sep; 125(9):1266-8. PubMed ID: 17846369
[No Abstract] [Full Text] [Related]
13. Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials.
Suñer IJ; Kokame GT; Yu E; Ward J; Dolan C; Bressler NM
Invest Ophthalmol Vis Sci; 2009 Aug; 50(8):3629-35. PubMed ID: 19255158
[TBL] [Abstract][Full Text] [Related]
14. Age-Related Macular Degeneration and Quality of Life in Latinos: The Los Angeles Latino Eye Study.
Choudhury F; Varma R; Klein R; Gauderman WJ; Azen SP; McKean-Cowdin R;
JAMA Ophthalmol; 2016 Jun; 134(6):683-90. PubMed ID: 27124819
[TBL] [Abstract][Full Text] [Related]
15. Quality of life among patients with age-related severe macular degeneration assessed using the NEI-VFQ, HADS-A, HADS-D and SF-36 tests. A cross-sectional study.
Inan S; Cetinkaya E; Duman R; Dogan I; Inan UÜ
Sao Paulo Med J; 2019 May; 137(1):25-32. PubMed ID: 31116266
[TBL] [Abstract][Full Text] [Related]
16. Public health impact of neovascular age-related macular degeneration treatments extrapolated from visual acuity.
Bandello F; Lafuma A; Berdeaux G
Invest Ophthalmol Vis Sci; 2007 Jan; 48(1):96-103. PubMed ID: 17197522
[TBL] [Abstract][Full Text] [Related]
17. Computerized model of cost-utility analysis for treatment of age-related macular degeneration.
Fletcher EC; Lade RJ; Adewoyin T; Chong NV
Ophthalmology; 2008 Dec; 115(12):2192-8. PubMed ID: 18930556
[TBL] [Abstract][Full Text] [Related]
18. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial.
Chang TS; Bressler NM; Fine JT; Dolan CM; Ward J; Klesert TR;
Arch Ophthalmol; 2007 Nov; 125(11):1460-9. PubMed ID: 17998507
[TBL] [Abstract][Full Text] [Related]
19. Vision-related quality of life in patients suffering from age-related macular degeneration.
Berdeaux GH; Nordmann JP; Colin E; Arnould B
Am J Ophthalmol; 2005 Feb; 139(2):271-9. PubMed ID: 15733988
[TBL] [Abstract][Full Text] [Related]
20. Validation of the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) in age-related macular degeneration.
Orr P; Rentz AM; Margolis MK; Revicki DA; Dolan CM; Colman S; Fine JT; Bressler NM
Invest Ophthalmol Vis Sci; 2011 May; 52(6):3354-9. PubMed ID: 21282568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
